2. Altman, DG, Schulz, KF, Moher, D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663–694.
3. Atkins, D. Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs. Med Care. 2007;45 (Suppl 2):S16–S22.
4. Chan, AW, Hrobjartsson, A, Haahr, MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291:2457–2465.
5. Dumville, JC, Torgerson, DJ, Hewitt, CE. Reporting attrition in randomized controlled trials. BMJ. 2006;332:969–971.
6. Ethgen, M, Boutron, I, Baron, G, et al. Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease. Ann Intern Med. 2005;143:20–25.
7. Fortin, M, Dionne, J, Pinho, G, et al. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med. 2006;4:104–108.
9. Gartlehner, G, Hansen, RA, Nissman, D, et al. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol. 2006;59:1040–1048.
11. Godwin, M, Ruhland, L, Casson, I, et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol. 2003;3:28.
12. Gross, CP, Mallory, R, Heiat, A, et al. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med. 2002;137:10–16.
15. Haynes, B. Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. BMJ. 1999;319:652–653.
16. Hazell, L, Shakir, SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–396.
17. Hewitt, C, Hahn, S, Torgerson, DJ, et al. Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals. BMJ. 2005;330:1057–1058.
18. Huwiler-Muntener, K, Juni, P, Junker, C, et al. Quality of reporting of randomized trials as a measure of methodological quality. JAMA. 2002;287:2801–2804.
19. Ioannidis, JP, Evans, SJ, Gotzsche, PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781–788.
20. MacRae, KD. Pragmatic versus explanatory trials. Int J Technol Assess Health Care. 1989;5:333–339.
21. Malmivaara, A, Koes, BW, Bouter, LM, et al. Applicability and clinical relevance of results in randomized controlled trials: the Cochrane review on exercise therapy for low back pain as an example. Spine. 2006;31:1405–1409.
22. Moher, D, Cook, DJ, Eastwood, S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Onkologie. 2000;23:597–602.
23. Moher, D, Schulz, KF, Altman, D. The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials 2001. Explore (NY). 2005;1:40–45.
24. Mullner, M, Matthews, H, Altman, DG. Reporting on statistical methods to adjust for confounding: a cross-sectional survey. Ann Intern Med. 2002;136:122–126.
25. Mulrow, CD. Rationale for systematic reviews. BMJ. 1994;309:597–599.
27. Plint, AC, Moher, D, Morrison, A, et al. Does the CONSORT checklist improve the quality of reports of randomized controlled trials? A systematic review. Med J Aust. 2006;185:263–267.
28. Schwartz, D, Lellouch, J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20:637–648.
29. Slutsky, J, Atkins, D, Chang, S, et al. Comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol. 2008 [Epub ahead of print].
30. Sokka, T, Pincus, T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum. 2003;48:313–318.
31. Zwarenstein, M, Treweek, S, Gagnier, JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390.